Brian Skorney
Stock Analyst at Baird
(3.40)
# 809
Out of 4,814 analysts
103
Total ratings
42.47%
Success rate
4.36%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Maintains: Outperform | $72 → $102 | $69.95 | +45.82% | 3 | Mar 27, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $50 → $55 | $38.63 | +42.38% | 5 | Feb 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $940 → $759 | $563.16 | +34.78% | 13 | Feb 5, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $46 | $8.18 | +462.69% | 1 | Dec 13, 2024 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $30 | $13.58 | +120.91% | 1 | Dec 13, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $14 → $5 | $0.33 | +1,423.46% | 4 | Nov 29, 2024 | |
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $26 → $20 | $5.13 | +289.86% | 6 | Nov 26, 2024 | |
| BIIB Biogen | Maintains: Outperform | $294 → $300 | $118.61 | +152.93% | 16 | Nov 15, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $200 → $193 | $53.79 | +258.80% | 9 | Nov 7, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $80 → $95 | $104.53 | -9.12% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $5.06 | +394.07% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $10 | $2.21 | +353.51% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $277.29 | -22.46% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $58 → $60 | $20.35 | +194.84% | 2 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $100.10 | +79.82% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $2.71 | +933.21% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $62 | $30.40 | +103.95% | 4 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $5.96 | +554.36% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $35.16 | +79.21% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $489.10 | -33.55% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $15.15 | -33.97% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $2.10 | +12,757.14% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $3.16 | +90.17% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $1.30 | +22,976.92% | 3 | May 7, 2018 |
Soleno Therapeutics
Mar 27, 2025
Maintains: Outperform
Price Target: $72 → $102
Current: $69.95
Upside: +45.82%
Mirum Pharmaceuticals
Feb 27, 2025
Maintains: Outperform
Price Target: $50 → $55
Current: $38.63
Upside: +42.38%
Regeneron Pharmaceuticals
Feb 5, 2025
Maintains: Neutral
Price Target: $940 → $759
Current: $563.16
Upside: +34.78%
Dyne Therapeutics
Dec 13, 2024
Initiates: Outperform
Price Target: $46
Current: $8.18
Upside: +462.69%
Benitec Biopharma
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $13.58
Upside: +120.91%
Applied Therapeutics
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $0.33
Upside: +1,423.46%
Enanta Pharmaceuticals
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $5.13
Upside: +289.86%
Biogen
Nov 15, 2024
Maintains: Outperform
Price Target: $294 → $300
Current: $118.61
Upside: +152.93%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $200 → $193
Current: $53.79
Upside: +258.80%
Gilead Sciences
Nov 7, 2024
Maintains: Neutral
Price Target: $80 → $95
Current: $104.53
Upside: -9.12%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $5.06
Upside: +394.07%
Oct 23, 2024
Maintains: Outperform
Price Target: $32 → $10
Current: $2.21
Upside: +353.51%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $277.29
Upside: -22.46%
Sep 23, 2024
Maintains: Outperform
Price Target: $58 → $60
Current: $20.35
Upside: +194.84%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $100.10
Upside: +79.82%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $2.71
Upside: +933.21%
May 23, 2024
Maintains: Outperform
Price Target: $52 → $62
Current: $30.40
Upside: +103.95%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $5.96
Upside: +554.36%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $35.16
Upside: +79.21%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $489.10
Upside: -33.55%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $15.15
Upside: -33.97%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $2.10
Upside: +12,757.14%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $3.16
Upside: +90.17%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $1.30
Upside: +22,976.92%